Nelson K.Y. Wong

BC Cancer Agency — Canada

Medicine · Health Sciences

14h-index680citations77works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(23), Prostate Cancer Treatment and Research(12), Cancer Mechanisms and Therapy(11), Biochemical and Molecular Research(9), Cancer therapeutics and mechanisms(7)

Publications77 total

Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations
Translational Oncology·2025Open Access
Supplementary Figure 5 from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Figure 1 from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Methods from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Figure 3 from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Data from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Figure 2 from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Figure 4 from 5′-<i>S</i>-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
2025Open Access
Supplementary Figure S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Figure S3 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Figure Legends from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Table S1 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Table S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Figure S4 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer
Translational Cancer Research·2025Open Access
Data from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Figure S2 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
Supplementary Table S3 from Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
2025Open Access
5′- <i>S</i> -(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers
Molecular Cancer Therapeutics·2025Open Access
Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
Molecular Cancer Research·2025· 2 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Yen‐Yi Lin(21), Colin C. Collins(21), Stanislav Volik(14), Yuzhuo Wang(14), Mark Carey(13), Marta Llauradó Fernández(12), Hui Xue(11), Amy Dawson(9), Joshua Hoenisch(9), Anne Haegert(8), Gabriel E. DiMattia(8), Dong Lin(7), Stéphane Le Bihan(6), Mohamed K. Khan(6), Martin Gleave(6), Thomas Doerksen(6), Fuqiang Ban(6), Shawn Aderson(6), Zhongye Dai(6), Ivica Bratanovic(6)